Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV) ...

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV) ...

Late-breaking data show infant respiratory syncytial virus (RSV) hospitalizations reduced by 69% in Spain following Beyfortus-only immunization targeted to all infants and 26.7% in the UK ...

Beyfortus administration can be timed to coincide with the RSV season. Beyfortus has been approved for use in the US, the EU, China, Japan, and many other countries around the world.

Experts say new immunisation program working, but some babies missing outThe number of Australian babies admitted to hospital ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

AstraZeneca and Sanofi's Beyfortus, a monoclonal antibody approved in July 2023, is the first preventive option specifically designed to protect the broad infant population through its first RSV ...